NCT03587376View on ClinicalTrials.gov

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 30, 2018

Primary Completion Date

August 23, 2018

Study Completion Date

August 23, 2018

Conditions

Alzheimer Disease

Interventions

DRUG

Atabecestat

Blood samples will be collected from participants previously treated with atabecestat.

Trial Locations (5)

2660

Ziekenhuis Hoge Beuken, Hoboken

20251

CTC North GmbH & Co. KG, Hamburg

75010

Hôpital Fernand Widal, Paris

08014

Fundacion Ace, Barcelona

141 86

Minnesmottagningen, M51, Stockholm

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT03587376 - Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat) | Biotech Hunter | Biotech Hunter